1st Quarter - Report

ACADEMY OF MANAGED CARE PHARMACY for ACADEMY OF MANAGED CARE PHARMACY

Firm
Client
Income
—
Expenses
$45,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization. Meeting with the Department of Health and Human services on proposal to restrict the use of rebates under Medicare and Medicaid

LobbyistCovered position, as disclosed
MARY JO CARDEN Vice President, Government & Pharmacy Affairs
CHRISTOPHER J. TOPOLESKI New —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Pharmacy PHA

Communication and correspondence in opposition to S. 657, Drug Price Transparency Act (Braun), support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (no introduced legislation to date)

LobbyistCovered position, as disclosed
MARY JO CARDEN New Vice President, Government & Pharmacy Affairs
CHRISTOPHER J. TOPOLESKI —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 659 (116th), S. 657 (116th), H.R. 965 (116th), S. 340 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.